HiberCell and Merck to Evaluate HC-7366 + WELIREG (belzutifan) in Ph 1b Study of ccRCC Patients
“We are excited to collaborate with Merck to evaluate HC-7366 in combination with belzutifan,” said Jonathan Lanfear, President & CEO of HiberCell. “We are also excited to announce that one of the scientific leaders within the RCC space, Dr. Robert Motzer, will be our lead PI for this important trial. We expect this study to build on what we have demonstrated preclinically, showing that the combination of these two therapies has the potential to significantly broaden and deepen patient responses relative to belzutifan alone. This trial will also build on the data from our ongoing Ph1a/1b monotherapy studies for HC-7366 in solid tumors. We are eager to pursue this investigational combination in a setting where additional treatment options for patients are needed.”
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000